Clinical Drug Testing Biochip
The multiplex Clinical Drug Testing Biochip provides clinicians with a semi-quantitative comprehensive drug screen in patients for various medical reasons including but not limited to; those presenting acute overdose symptoms, screening for clinical trial eligibility and recurring prescription management. The preliminary test result will determine recent illicit drug use, facilitating clinical management.
Analytes Detected
Analytes | |||
Acetaminophen | Amphetamine | Barbiturates | Benzodiazepines 1 (Oxazepam) |
Benzodiazepines 2 (Clonazepam) | Buprenorphine | BZG/Cocaine | Creatinine (Urine only) |
Dextromethorphan | EtG (Ethyl Glucuronide) | Fentanyl | Haloperidol |
Ketamine | MDMA | Meprobamate | Methadone |
Methamphetamine | Methaqualone | Opiate | Oxycodone |
PCP (Phencyclidine) | Pregabalin | Propoxyphene | Salicylates |
TCA (Tricyclic Antidepressants) | THC (Cannabinoids) | Tramadol | Zolpidem |
6-MAM | Xylazine (Blood Only) |
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.